Physiology and Pharmacology of Effects of GLP-1-based Therapies on Gastric, Biliary and Intestinal Motility
Open accessThe DOI matches its Crossref record; 159 of the 161 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) receptor agonists and the dual GLP-1- and glucose-dependent insulinotropic polypeptide receptor co-agonist tirzepatide (referred to here collectively as “GLP-1-based therapy”) are incretin-based therapies being used increasingly in the management of both type 2 diabetes and obesity. They are now recognized to have beneficial effects beyond improved glycemic control and weight loss, including cardiovascular and renal protection. GLP-1-based therapy also slows gastric emptying, which has benefits (lowering postprandial glucose), but also potential risks (eg, hypoglycemia in individuals on insulin or sulphonylurea therapy). Their effects on the gallbladder may also be beneficial, contributing to reducing postprandial triglycerides, but they also potentially increase the risk of biliary disease. In this review, we summarize the effects of GLP-1 and incretin-based therapeutics on gastric, biliary and small intestinal function. An improved understanding of these effects will optimize the use of these drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The capacity of GLP-1 RAs to decelerate gastric emptying to levels indicative of gastroparesis raises concerns regarding potential intestinal obstruction and perioperative aspiration risk.”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Both animal and human studies have shown that increased GLP-1 activity reduces intestinal motility [23].”
From Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning (2025) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
Nauck, M., Frid, A., Hermansen, K., Shah, N. S., Tankova, T., Mitha, I. H., Zdravkovic, M., Düring, M., Matthews, D. R., & for the LEAD-2 Study Group (2009) · Diabetes Care · doi:10.2337/dc08-1355 · Cited by 1,129
Self-citationDrucker, D. J., Buse, J. B., Taylor, K., Kendall, D. M., Trautmann, M., Zhuang, D., & Porter, L. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61206-4 · Cited by 1,070
Anti-obesity drug discovery: advances and challenges
Müller, T. D., Blüher, M., Tschöp, M. H., & DiMarchi, R. D. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00337-8 · Cited by 1,021
Ghoos, Y. F., Maes, B. D., Geypens, B. J., Mys, G., Hiele, M. I., Rutgeerts, P. J., & Vantrappen, G. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90640-x · Cited by 946
The interdigestive myo‐electric complex of the stomach and small bowel of dogs.
Code, C. F., & Marlett, J. A. (1975) · The Journal of Physiology · doi:10.1113/jphysiol.1975.sp010891 · Cited by 713
Blundell, J., Finlayson, G., Axelsen, M., Flint, A., Gibbons, C., Kvist, T., & Hjerpsted, J. B. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12932 · Cited by 693
Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in man
Wettergren, A., Schjoldager, B., Mortensen, P. E., Myhre, J., Christiansen, J., & Holst, J. J. (1993) · Digestive Diseases and Sciences · doi:10.1007/bf01316798 · Cited by 670
Filippatos, T. D., Panagiotopoulou, T. V., & Elisaf, M. S. (2014) · The Review of Diabetic Studies · Cited by 560
Research works printed but not linked: 1
- Jalleh, 2024, [Abstract] short-acting glucagon-like peptide-1 receptor agonist therapy delays gastric emptying during insulin-induced hypoglycaemia as well as euglycaemia in type 2 diabetes, Diabetologia, 67, S45
Cited by
Glucagon-like peptide-1 receptor agonists and muscle mass effects
Ceasovschih, A., Asaftei, A., Lupo, M. G., Kotlyarov, S., Bartušková, H., Balta, A., Sorodoc, V., Sorodoc, L., & Banach, M. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107927 · Cited by 64
Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning
Kim, J. A., & Yoo, H. J. (2025) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2025.0242 · Cited by 71
“Both animal and human studies have shown that increased GLP-1 activity reduces intestinal motility [23].”
Muzurović, E. M., Katsiki, N., Volčanšek, Š., Plescia, F., Rizzo, M., & Mantzoros, C. S. (2026) · Metabolism · doi:10.1016/j.metabol.2026.156494 · Cited by 25
GLP-1 receptor agonists in IBD: exploring the crossroads of metabolism and inflammation
Migliorisi, G., Gabbiadini, R., Buono, A. D., Ferraris, M., Privitera, G., Petronio, L., Bertoli, P., Bezzio, C., & Armuzzi, A. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1610368 · Cited by 26
Saha, B., Kamalumpundi, V., & Codipilly, D. C. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.09.017 · Cited by 26
Optimizing Body Composition During Weight Loss: The Role of Amino Acid Supplementation
Cannavaro, D., Leva, F., Caturano, A., Berra, C., Bonfrate, L., & Conte, C. (2025) · Nutrients · doi:10.3390/nu17122000 · Cited by 15
Moiz, A., Peters, T. M., Tsoukas, M. A., Yu, O. H. Y., Filion, K. B., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103991 · Cited by 14
Ultrasonographic assessment of gastric and gallbladder dynamics in human health and disease
Ciaula, A. D., Khalil, M., & Portincasa, P. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-03905-7 · Cited by 10
“…affected by the use of drugs able to inhibit (as somatostatin or somatostatin analogs [17], estrogens [116], 5-hydroxy-tryptamine inhibitors [117], GLP-1 receptor agonists[86]) or to enhance (as prokinetics, erythromycin or clarithromycin [118], cholestyramine [119]) gallbladder dynamics.”
Practical application of semaglutide: From evidence-based research to expert decisions
Салухов, В. В., Galstyan, G. R., Khalimov, Y. S., Бакулин, И. Г., Cherkashin, D. V., Shadrichev, F. E., & Sukhotskaia, N. A. (2025) · Meditsinskiy sovet = Medical Council · doi:10.21518/ms2025-185 · Cited by 8
The National Psoriasis Foundation Primer on GLP-1 Receptor Agonists in Psoriasis: A Review
Sheth, S., Merola, J. F., Weber, B. N., Prussick, R. B., Yeung, J., Liu, C., Glick, B. P., Reddy, S. M., Cook-Bolden, F. E., Wallace, E. B., et al. (2026) · JAMA Dermatology · doi:10.1001/jamadermatol.2026.0859 · Cited by 17
Dobbie, L. J., Tolvanen, L., Alves, D., Baker, J. L., Bez, N. S., Birney, S., Bogl, L. H., Brown, A., Bullo, M., Clare, K., et al. (2026) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(26)00122-1 · Cited by 8
Jogani, V. G., Elfadil, O. M., Varayil, J. E., & Mundi, M. S. (2025) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001294 · Cited by 10
Pharmacotherapy for Obesity: Recent Updates
Fredrick, T. W., Camilleri, M., & Acosta, A. J. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s497904 · Cited by 33
Umapathysivam, M. M., Araldi, E., Hastoy, B., Dawed, A. Y., Vatandaslar, H., Mayrhofer, J. E., Lindquist, P., Silva, P. N., Goga, A., Trüllinger, G. O., et al. (2026) · Genome Medicine · doi:10.1186/s13073-026-01630-0 · Cited by 15
Self-citationGLP‐1 Receptor Agonists and Weight Loss: A Critical Review of Mechanisms
Rutigliani, G., Cross, T.-W., de Jong, E., Glover, E. S., Mendoza, I. D., Adisa, M., Tomoo, K., Zhou, X., & Mattes, R. D. (2026) · Obesity Reviews · doi:10.1111/obr.70148 · Cited by 5
Ilie, I. R. P., Ghibu, S., Butucă, A., Dobrea, C. M., Frum, A., Homorodean, C., Chiş, A. A., & Morgovan, C. (2026) · Pharmaceuticals · doi:10.3390/ph19060876 · Cited by 7
Dinkov, B. (2026) · Biomedicines · doi:10.3390/biomedicines14061235 · Cited by 4
“Additional indirect mechanisms include delayed gastric emptying [83], which modifies intestinal transit and pH in a direction potentially favorable for A. muciniphila colonization in the large intestine [84].”
Gadelmawla, A. F., Hammad, N., Atta, K., Diaa, A., Abouzkaly, F., Soni, K., Kelkar, R., Agrawal, S. P., Ahmed, R., Jain, H., et al. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.02.030 · Cited by 4
Quinine: rediscovery of an old glucose-lowering drug
Henquin, J. (2025) · Diabetologia · doi:10.1007/s00125-025-06416-4 · Cited by 3
Gut Hormones and Inflammatory Bowel Disease
Weng, J., & Lo, C. C. (2025) · Biomolecules · doi:10.3390/biom15071013 · Cited by 7
“In contrast, native GLP-1 or GLP-1R agonists inhibit small intestinal motility in healthy subjects and patients with type 2 diabetes or irritable bowel syndrome [152–156].”
Lahoud, C., Kreidieh, M., & Deeb, L. S. (2025) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-025-01961-w · Cited by 3
“The most pronounced delay is observed with short-acting agents, while long-acting agents (including both oral and injectable) show attenuation of this effect over time due to tachyphylaxis [20–22].”
Su, Q., Yang, S., & Liu, Q. (2025) · Medicine · doi:10.1097/md.0000000000044650 · Cited by 2
“[44] Our study boasts several key strengths.”
Hsiao, C.-C., Chen, J.-J., Huang, S.-C., Yen, C., Ho, W.-Y., Fang, Y.-W., Chen, M., Yang, J. H., & Tsai, M. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113115 · Cited by 3
Sutton, S., Ferguson, Q., Gimpelevich, R., & Hemadeh, O. (2026) · JCEM Case Reports · doi:10.1210/jcemcr/luag019 · Cited by 2
Balakumar, P., Khan, N. A., Easwaran, V., & Orayj, K. M. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113155 · Cited by 1
Glucagon-like peptide-1 drugs, gastrointestinal function and critical illness
Nadkarni, A., Deane, A. M., & Plummer, M. P. (2026) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001376 · Cited by 3
Self-citationCiaula, A. D., Khalil, M., Garruti, G., & Portincasa, P. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101056 · Cited by 2
Introduction to G-protein-Coupled Receptors (GPCRs): Structure and Function
Paul, S., Tiwari, P., Kumar, M. V., Samal, P. K., & Madhyastha, H. (2026) · Springer eBooks · doi:10.1007/978-981-95-9081-0_1 · Cited by 1
Alanazi, M., Al‐kuraishy, H. M., Mohamed, A. A., Abass, S. A., Shokr, M. M., Alruwaili, M., & Batiha, G. E. (2026) · Current Nutrition Reports · doi:10.1007/s13668-026-00773-1 · Cited by 1
“The effects are typically moder - ate in clinical practice; yet, they reinforce the notion that inhibit DPP-4 can enhance communication between the stomach and central nervous system [123, 124].”
Whitledge, J. D., Kennedy, J. M., Watson, C. J., Malley, C., Simone, K. E., & Neavyn, M. (2025) · Journal of Medical Toxicology · doi:10.1007/s13181-025-01075-8 · Cited by 1
Prosecký, R., & Karoliová, K. H. (2025) · Klinická farmakologie a farmacie · doi:10.36290/far.2025.041
The Physiology of Semaglutide in Relation to Glucagon Like Peptide-1: A Comprehensive Review
Barakat, G. M., Hassan, S. E. H., Issa, H., & Ramadan, W. (2025) · Current Drug Therapy · doi:10.2174/0115748855404783250917112146
Harnessing the gut-brain axis in the treatment of type 2 diabetes mellitus and obesity
Kotucha, K., Kapłon, K., Moś, M., Fiegler-Rudol, J., Pietryszyn-Bilińska, A., Dynarowicz, K., Aebisher, D., Wiench, R., & Kawczyk‐Krupka, A. (2025) · European Journal of Clinical and Experimental Medicine · doi:10.15584/ejcem.2025.4.24
Steven, C., Skylynn, T., Bardya, H., Megha, B., Helen, V., Lee, D., Entabi, F., & Pemminati, S. (2026) · Cureus · doi:10.7759/cureus.100704 · Cited by 2
INTERNATIONAL GUIDELINES ON PERIOPERATIVE MANAGEMENT OF GLP-1 RECEPTOR AGONISTS: A NARRATIVE REVIEW
Grela, K., Grygorowicz, A., Baran, K., Ględa, M., Szyszka, M., Radecka, W., Kozak, W., Szreiber, A., Nowacka, K., Jabłoński, K., et al. (2025) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.4(48).2025.4724
Борисовна, Т. Т., Ardatskaya, M. D., Maslovskii, L. V., & Minushkin, O. N. (2025) · Consilium Medicum · doi:10.26442/20751753.2025.12.203514
Rolak, S. C., Frazier, R., Harris, L. A., Lunsford, T. N., Yang, M., & Hasler, W. L. (2026) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2026.02.025
Sillassen, C. D. B., Faltermeier, P., Bjerg, J. L., Andersen, R. K., Petersen, J. J., Andersen, P. B., Kamp, C. B., Karlsson, F., Grand, J., Domínguez, H., et al. (2026) · BMC Medicine · doi:10.1186/s12916-026-04824-w · Cited by 3
“The gastrointestinal adverse effects of tirze-patide and other incretin-based therapies are thought to be largely related to effects on the gastrointestinal tract, including delayed gastric emptying [74].”
Acute ischaemic colitis after initiation of tirzepatide in an elderly patient with type 2 diabetes
Cuomo, G., Sena, A. D., Gammaldi, V., D'Onofrio, R., Ciliberti, V., Luca, L. D., D’Antonio, A., Nuzzo, V., & Tirelli, P. (2026) · Emergency Care Journal · doi:10.4081/ecj.2026.14970
GLP-1RA and aspiration risk in moderate sedation for endoscopy
Costanza, L., White, E. B., Chaturvedi, A., Kang, S., Chau, C. A., Shaw, K. M., & Xi, A. S. (2026) · JCA advances. · doi:10.1016/j.jcadva.2026.100239
Riaz, L., Ajmal, A., Siddiquei, H., Memon, U., & Amin, J. H. J. (2026) · Annals of Medicine and Surgery · doi:10.1097/ms9.0000000000005086
“Emerging evidence also suggests functional interaction between enteric neurons and interstitial cells of Cajal, potentially amplifying inhibitory neuromuscular signaling [ 1 , 3 ] .”
InfluentialElatrebi, S. F., Abuyadek, R. M., Abdelbar, S. M. M., Ahmad, M. S., Ayyad, M., Quoritem, M. A., Majid, R. O. A., Arafat, M., Amgad, A., & Alnagar, A. (2026) · World Journal of Transplantation · doi:10.5500/wjt.120572
Preoperative fasting for patients who take GLP-1 receptor agonists: should we Sip Til Send?
Lowes, L. (2026) · Advances in Perioperative Care · doi:10.14324/111.444/apoc.3777
Qian, Z., & Jiang, N. (2026) · PLoS ONE · doi:10.1371/journal.pone.0351731
Beig, J., Ta, J., Jones, S., Scott, E., Sofi, K., Osler, F., Jansen, M., & Chhabra, P. (2026) · Chronic Diseases and Translational Medicine · doi:10.1002/cdt3.70059 · Cited by 1
“…are expressed beyond pancreatic tissue, including gastrointestinal smooth muscle, renal tissue, vagal afferent pathways, and central autonomic centers, including the appetite center, providing the basis for both metabolic benefits and clinically relevant gastrointestinal motility effects [33].”
Baker, F., Melhem, M., Kalnizki, O., Khader, M., Dardik, M., Tatour, M., & Hazzan, R. (2026) · BMJ Open Gastroenterology · doi:10.1136/bmjgast-2026-002360
Nguefang, G., Boateng, S., Issaka, Y., Landa, E. L., Gyabaah, S., Mekontso, J. G. K., & Njei, B. M. (2026) · Obesity Surgery · doi:10.1007/s11695-026-08864-2
“GLP-1 RA are known to slow gastric emptying and reduce gastrointestinal motility through effects on the enteric nervous system [39, 40], yet meta-analytic data in non-surgical populations demonstrate that GLP-1 RA therapy likely has little or no effect on intes - tinal obstruction overall [ 41 ].”
Kim, T., Seo, J., Kang, S., Kim, H. K., Lee, B., Lee, J., & Go, G. (2026) · Food Science and Biotechnology · doi:10.1007/s10068-026-02259-w
Kommentar zu GLP-1- und GIP-Agonisten vor Gastroskopie aussetzen oder fortführen?
Quast, D. R. (2026) · Diabetologie und Stoffwechsel · doi:10.1055/a-2858-2463
Self-citationGómez-Maldonado, I., Rodríguez-Arana, A., Tamayo-Pinzón, A., Albornoz-Suárez, J. E., Lopez-Franco, M. J., Mejia-Manrique, J. A., Forero-Caycedo, J. J., Rojas-Rodríguez, L. C., Buitrago-Ricaurte, N., Gaviria-Carrillo, M., et al. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167108
Fappi, A., Shabrish, V., Hollomon, H., Islam, T., Zhang, X., Razani, B., Klein, S., & Mittendorfer, B. (2026) · American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2026.101468 · Cited by 2
Implications of Medications in Gastrointestinal Motility
Peixoto, A., Araújo, F. D., Maciel, P., Frias, J., & Câmara, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27658-3.00025-1
Opioid Toxicity Associated With Tirzepatide in a Patient on Chronic Oral Morphine
Mataraarachchi, N. E., Dellinger, O. D., & Babakhanians, A. (2026) · Cureus · doi:10.7759/cureus.115380
“A pharmacologic consequence of GLP-1 receptor agonism is delayed gastric emptying, mediated through GLP-1-and GIP-receptor-dependent inhibition of antral motility and pyloric contraction [3,4].”
Seo, J., Choi, S., Kim, N., Kim, H., & Lim, H.-S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1846164
“These findings suggest that, compared with the pooled total population, patients with obesity may show a greater early increase in baseline AE risk after treatment initiation and a larger decrease in the duration of non-drug effects (Jalleh et al., 2025a).”
Beyond efficacy: the treatment lifecycle of incretin and multi-receptor agonists
Rabbani, S. A., El-Tanani, M., Matalka, I. I., & Rizzo, M. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1902185
“The events were mostly mild to moderate, predominantly during dose escalation, and often attenuated over time, consistent with clinical adaptation and tachyphylaxis of the gastric emptying effect (36, 37, 50).”
InfluentialNiyomugabo, A. P., Ntakirutimana, L., Izabayo, P., Isingizwe, C., Onaadepo, O., & Alagbonsi, A. I. (2026) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188261492402 · Cited by 3
Wu, Y., Li, K., Wang, Y., Chen, Z., Shi, M., & Zhao, J. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1941948
Amoyel, M., Lebtahi, R., Poghosyan, T., Gall, M. L., & Soliman, H. (2026) · Comprehensive physiology · doi:10.1002/cph4.70275
“Scintigraphic studies, predominantly assessing solid-phase emptying, have consistently demonstrated delayed gastric emptying after acute administration of GLP-1 receptor agonists (Jalleh, Marathe, et al. 2024; Hiramoto et al. 2024; Jalleh, Plummer, et al. 2024; Jalleh, Rayner, et al. 2024).”
Ismaiel, A., & Dumitrascu, D. L. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102146
Current Evidence and Practical Considerations for GLP-1 Receptor Agonists in Gynecologic Oncology
Neveu, J., Mateo-Kubach, P., Pervan, M., Meschini, T., Sabini, C., Martínez, Z. R. M., Loverro, M., Maureen, B., Villagrá, I., Del, M., et al. (2026) · International Journal of Gynecological Cancer · doi:10.1016/j.ijgc.2026.105660 · Cited by 2
Cholesterol Absorption: Mechanisms, Regulation, and Therapeutic Targets
Abdalqadir, N., & Adeli, K. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27658-3.00059-7
Metadata
- Authors
- Jalleh, R. J., Marathe, C. S., Rayner, C. K., Jones, K. L., Umapathysivam, M. M., Wu, T., Quast, D. R., Plummer, M. P., Nauck, M. A., & Horowitz, M.
- Affiliations
- Royal Adelaide Hospital (AU)
- The University of Adelaide (AU)
- St. Josef-Hospital (DE)
- Universitätsmedizin Greifswald (DE)
- Corresponding author
- Horowitz, Michael
- ORCID
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2024-11-21
- Volume
- 166
- Issue
- 1
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- PMC
- PMC11630531
- OpenAlex
- W4404599306
- Semantic Scholar
- 3cc381b931212977ce9dd942992d266b1a137aea
- Cited by
- 61
- References
- 161
- Citations by year
- 2026: 42 · 2025: 19
- FWCI
- 3.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Endocrinology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UniSA Research Outputs Repository (University of South Australia) (submittedVersion, other-oa)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Health Sciences › Medicine › Surgery › Bariatric Surgery and Outcomes
- Keywords
- GLP-1 receptor agonists, tirzepatide, incretin-based therapy, gastric emptying, gallbladder motility, biliary function, small intestine motility, type 2 diabetes, obesity, postprandial triglycerides, hypoglycemia, biliary tract diseases, gastrointestinal adverse effects
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Animals, Biliary Tract, Diabetes Mellitus, Type 2, Gastric Emptying, Gastrointestinal Motility, Humans, Hypoglycemic Agents, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.